PSY7 Increased Length and Cost of Hospital Stay in Inpatients with Iron Deficiency Anemia Experiencing Moderate-Severe Hypophosphatemia after Administration of Ferric Carboxymaltose

Intravenous (IV) iron is the mainstay of treatment for deficiency anemia (IDA), when oral cannot be used or there a need rapid delivery. Ferric carboxymaltose (FCM) widely IV preparation known to cause moderate/severe hypophosphatemia (serum phosphate <0.65mmol/L; <2mg/dL) in up 75% patients. This study aimed analyze length hospital stay (LoS) and related cost inpatients with no/mild versus post-FCM treatment. A patient-level model was developed evaluate LoS IDA various etiologies treated FCM at University College Hospital, London, UK (N=162 inpatients; 169 courses). costs were modeled patients (n=112 courses) (n=57 hypophosphatemia. Analyses conducted across 107 non-elective healthcare resource group (HRG) tariffs finite trimpoints weighted using NHS England Hospital Episode Statistics (HES). Costs calculated based on excess stays longer than HRG trimpoint. Mean 10.9 days (standard deviation [SD] 13.4 days) 18.0 (SD 19.8 days; p=0.0035) The analysis by showed an GBP 1,159 2,435 hypophosphatemia, difference 1,275 (+110%) per spell. Patients after experienced significantly HRG-based HES data that 110% higher associated hypophosphataemia may therefore represent additional substantial should considered future economic evaluations.